Evidence map›Paper›PMID 26598696›Full record

ReviewProceedings of the National Academy of Sciences of the United States of America2015

Progress in material design for biomedical applications.

Mark W Tibbitt, Christopher B Rodell, Jason A Burdick, Kristi S Anseth

Abstract readReview
In one paragraph

Review in Proceedings of the National Academy of Sciences of the United States of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Embracing complexity in biomaterials design.Biomaterials and biosystems · 2022
    Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mark W TibbittKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139;
Christopher B RodellDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104;
Jason A BurdickDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104;
Kristi S AnsethDepartment of Chemical and Biological Engineering and the BioFrontiers Institute, University of Colorado, Boulder, CO 80303 Kristi.Anseth@colorado.edu.

Funding

Dynamic Fibrous Scaffolds for Repairing Dense Connective TissuesR01AR056624 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI Jason A Burdick, Robert L Mauck · 2009 to 2026
$7.5M
Osteogenic Hydrogel Niches to Promote hMSC Migration and DifferentiationR01DE016523 · NIDCR · UNIVERSITY OF COLORADO AT BOULDER · PI ANSETH, KRISTI S. · 2005 to 2023
$6.2M
Engineering Developmental Microenvironments: Cartilage Formation and MaturationR01EB008722 · NIBIB · UNIVERSITY OF PENNSYLVANIA · PI BURDICK, JASON A, MAUCK, ROBERT L · 2009 to 2017
$3.0M
Localized Targeting of Matrix Proteases Following Myocardial InfarctionR01HL111090 · NHLBI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI BURDICK, JASON A, SPINALE, FRANCIS G · 2012 to 2015
$2.0M
Local delivery of TGF-beta inhibitors to treat mitral valve diseaseF32HL122009 · NHLBI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI TIBBITT, MARK WILLIAM · 2014 to 2017
$133k
NHLBI NIH HHS F32 HL122009NHLBI NIH HHS R01 HL111090NIAMS NIH HHS R01 AR056624NIBIB NIH HHS R01 EB008722NIDCR NIH HHS R01 DE016523
6 · The paper itself

Abstract

Biomaterials that interface with biological systems are used to deliver drugs safely and efficiently; to prevent, detect, and treat disease; to assist the body as it heals; and to engineer functional tissues outside of the body for organ replacement. The field has evolved beyond selecting materials that were originally designed for other applications with a primary focus on properties that enabled restoration of function and mitigation of acute pathology. Biomaterials are now designed rationally with controlled structure and dynamic functionality to integrate with biological complexity and perform tailored, high-level functions in the body. The transition has been from permissive to promoting biomaterials that are no longer bioinert but bioactive. This perspective surveys recent developments in the field of polymeric and soft biomaterials with a specific emphasis on advances in nano- to macroscale control, static to dynamic functionality, and biocomplex materials.

Indexed as

Biocompatible MaterialsHumansTissue EngineeringBiocompatible Materialsbiocomplexbiomaterialsdynamicsfeature controlsoft materials

Identifiers

PMID26598696
PMCPMC4664367

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.